Anna B. Chapman
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Topical delgocitinib in severe chronic hand eczema: an alternative to systemic therapy with practical considerations and economic impact.
Journal: Clinical and experimental dermatology
Published: February 05, 2026
Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
Journal: Nature communications
Published: December 17, 2021
Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
Journal: Nature communications
Published: October 19, 2020
T-cell phenotyping uncovers systemic features of atopic dermatitis and psoriasis.
Journal: The Journal of allergy and clinical immunology
Published: July 22, 2019
A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Journal: Health technology assessment (Winchester, England)
Published: April 14, 2017
Basosquamous carcinoma: appearance and reality.
Journal: Oxford medical case reports
Published: May 18, 2016
Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.
Journal: Lancet (London, England)
Published: January 26, 2016
Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis.
Journal: The Journal of investigative dermatology
Published: June 21, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026